Children's Cancer Group

Children's Cancer Group
Name	Children's Cancer Group
Abbreviation	CCG
Formation	1955
Dissolution	2000
Type	Research consortium
Headquarters	St. Jude Children's Research Hospital
Region served	United States, international collaborators
Leader title	Director

Contents

Children's Cancer Group The Children's Cancer Group was a United States–based clinical trials consortium focused on pediatric oncology that coordinated multicenter research and treatment protocols during the late 20th century. Founded amid evolving pediatric care at St. Jude Children's Research Hospital, Memorial Sloan Kettering Cancer Center, and regional children's hospitals, the group influenced standards of care across institutions such as Children's Hospital of Philadelphia and Dana–Farber Cancer Institute. Its operations intersected with national agencies including the National Cancer Institute and partnerships with academic centers like Johns Hopkins Hospital, Mayo Clinic, and University of Chicago.

History

The group's origins trace to postwar pediatric initiatives at St. Jude Children's Research Hospital, Children's Hospital Boston, and the University of California, San Francisco that paralleled developments at the National Institutes of Health, American Cancer Society, and the March of Dimes. Early meetings involved investigators from Memorial Sloan Kettering Cancer Center, Yale-New Haven Hospital, Columbia University Medical Center, and Cincinnati Children's Hospital Medical Center who sought cooperative trials for leukemia and solid tumors. Throughout the 1960s and 1970s the consortium expanded membership to centers such as Texas Children's Hospital, Seattle Children's Hospital, Mount Sinai Hospital (New York), and Roswell Park Comprehensive Cancer Center, coordinating multicenter protocols and data collection compatible with standards from Food and Drug Administration oversight. By the 1980s and 1990s CCG had integrated investigators from international institutions including Great Ormond Street Hospital, Hospital for Sick Children, Toronto, and research groups affiliated with Institut Gustave Roussy and University of Tokyo.

Governance included a central steering committee composed of principal investigators from major sites like St. Jude Children's Research Hospital, Children's Hospital of Philadelphia, Dana–Farber Cancer Institute, and Johns Hopkins Hospital, with protocol committees reflecting expertise from Memorial Sloan Kettering Cancer Center, Mayo Clinic, Duke University Medical Center, and Vanderbilt University Medical Center. Membership encompassed pediatric oncologists, pathologists, radiologists, and statisticians from centers such as Emory University Hospital, University of Michigan Hospitals, University of Pittsburgh Medical Center, and Cleveland Clinic. Administrative and data management functions coordinated with the National Cancer Institute and contract research organizations tied to Harvard Medical School and University of California, Los Angeles. Funding streams included grants from National Institutes of Health, support from American Cancer Society, and philanthropic contributions linked to St. Jude Children's Research Hospital donors.

The group designed and implemented randomized trials and phase studies addressing acute lymphoblastic leukemia, Wilms tumor, neuroblastoma, and sarcomas, collaborating with institutions like Children's Hospital Los Angeles, Hospital for Sick Children, Toronto, Great Ormond Street Hospital, and Institut Gustave Roussy. Landmark trials compared regimens used at Memorial Sloan Kettering Cancer Center, Dana–Farber Cancer Institute, and St. Jude Children's Research Hospital, while biostatistical analyses drew on methods from Harvard School of Public Health and Johns Hopkins Bloomberg School of Public Health. Pathology review panels included experts from Mayo Clinic and Massachusetts General Hospital, and imaging protocols linked research radiologists at University of Pennsylvania Health System and UCSF Medical Center. The group contributed to prognostic stratification frameworks adopted by the National Cancer Institute and informed molecular studies collaborating with laboratories at Cold Spring Harbor Laboratory and Salk Institute for Biological Studies.

CCG protocols refined combination chemotherapy, radiation schedules, and surgical timing for malignancies such as acute lymphoblastic leukemia, Hodgkin lymphoma, Wilms tumor, rhabdomyosarcoma, and osteosarcoma, with outcomes compared across cohorts treated at St. Jude Children's Research Hospital, Dana–Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Children's Hospital of Philadelphia. Reported survival improvements paralleled translational research from centers such as Fred Hutchinson Cancer Center, Sloan Kettering Institute, and University of Texas MD Anderson Cancer Center. Protocols adopted central review practices established with input from American Academy of Pediatrics committees and pathology contributions from Moffitt Cancer Center and Roswell Park Comprehensive Cancer Center, thereby standardizing staging and response criteria used in subsequent trials.

Throughout the 1990s the consortium engaged in joint initiatives with the National Cancer Institute and cooperative groups including Pediatric Oncology Group and international partners at Great Ormond Street Hospital and Hospital for Sick Children, Toronto. These alliances culminated in a formal consolidation with the Pediatric Oncology Group to form the Children's Oncology Group in 2000, integrating investigators from St. Jude Children's Research Hospital, Dana–Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Johns Hopkins Hospital, and other major pediatric centers. The merger aligned clinical trial portfolios with research networks at National Institutes of Health and collaborative genomics efforts linked to Broad Institute and Genome Institute at Washington University.

The consortium's legacy endures in standardized trial methodology, cooperative group infrastructure, and survival improvements documented in publications from collaborators at New England Journal of Medicine–affiliated investigators, contributors from Lancet Oncology studies, and reports coordinated with the National Cancer Institute. Its protocols informed long-term survivorship programs at institutions like St. Jude Children's Research Hospital, Dana–Farber Cancer Institute, Children's Hospital of Philadelphia, and UCLA Mattel Children's Hospital, and its data systems influenced cancer registries maintained by Centers for Disease Control and Prevention and international registries tied to International Society of Paediatric Oncology. The group's consolidation into the Children's Oncology Group ensured continuity of multicenter trials and sustained contributions from leading pediatric oncology centers including Mayo Clinic, Vanderbilt University Medical Center, and Cincinnati Children's Hospital Medical Center.

Category:Pediatric oncology organizations